clinical trial · NCT07150845
Phase 2b Study of EVO756 in Adults With Atopic Dermatitis
Atoptic DermatitisEVO756EVO756EVO756Placebo control
brief summary
This study will evaluate the efficacy and safety of different doses of EVO756 in adults with moderate to severe atopic dermatitis.
started
Aug 26, 2025
primary completion
Jul 1, 2026
completion
Jul 1, 2026
last updated
Apr 24, 2026
official title
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy and Safety of EVO756 in Adults With Atopic Dermatitis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol